As of Apr 20
| -0.08 / -1.65%|
The 7 analysts offering 12-month price forecasts for Keryx Biopharmaceuticals Inc have a median target of 7.00, with a high estimate of 9.00 and a low estimate of 5.00. The median estimate represents a +47.06% increase from the last price of 4.76.
The current consensus among 7 polled investment analysts is to Buy stock in Keryx Biopharmaceuticals Inc. This rating has held steady since April, when it was upgraded from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.